Article Information
History
- January 16, 2021.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Author Information
- Sophie A. Bell, BA*,1,
- Hannah R. Cohen, BS*,1,
- Seonjoo Lee, PhD2,3,
- Hyun Kim, PhD1,6,
- Adam Ciarleglio, PhD4,
- Howard Andrews, PhD2,
- Andres M. Rivera, MS5,
- Kay Igwe, MS5,
- Adam M. Brickman, PhD5,
- D.P. Devanand, MD1,6,
- Philip D. Harvey, PhD7,
- Lon S. Schneider, MD8 and
- Terry E. Goldberg, PhD1,6,#
- 1Division of Geriatric Psychiatry, New York State Psychiatric Institute, New York, NY, USA
- 2Department of Biostatistics, Mailman School of Public Health, Columbia University, New York, NY, USA
- 3Division of Mental Health Data Science, New York State Psychiatric Institute, New York, NY, USA
- 4Department of Biostatistics and Bioinformatics, Milken Institute School of Public Health, The George Washington University, Washington DC, USA
- 5Department of Neurology, Taub Institute for Research in Alzheimer’s Disease and the Aging Brain, and Gertrude H. Sergievsky Center, Vagelos College of Physicians and Surgeons, Columbia University, New York, NY, USA
- 6Department of Psychiatry, Columbia University Medical Center, New York, NY, USA
- 7University of Miami Miller School of Medicine, Miami VA Medical Center, Miami, Florida, USA
- 8University of Southern California Keck School of Medicine, Los Angeles, CA, USA
- ↵#Corresponding Author: Terry E. Goldberg, PhD, Columbia University Medical Center, 1051 Riverside Drive, Room 2409, New York, New York 10032, Email: teg2117{at}cumc.columbia.edu
↵* Equal contributions to authorship
Posted January 16, 2021.
Development of Novel Measures for Alzheimer’s Disease Prevention Trials (NoMAD)
